Home > Products > CD3 & HIV-1 gp41 > Recombinant Human Anti-CD3 x Human Anti-HIV-1 gp41 Bispecific Antibody (Bibody)

Recombinant Human Anti-CD3 x Human Anti-HIV-1 gp41 Bispecific Antibody (Bibody)  (CAT#: BIBD-H261)

Recombinant Anti-CD3 x Anti-HIV-1 gp41 Bispecific Antibody (Bibody) is a Fab-scFv format that uses heterodimeric Fab as a scaffold, and a scFv region linked to one of its heavy (Fd) or light (L) chain. The scFv of the anti-CD3 specificity is fused to the anti-CD3 heavy or light chain of the Fab. This BsAb can retarget T cells to HIV-1 infected cells. It is designed for the research of HIV-1 infection, AIDS therapy.
Datasheet INQUIRY

Specifications

Targets
CD3 & HIV-1 gp41
Type
Bibody
Species Reactivity
Human
Application
FuncS; Promising therapeutic agent
Related Disease
HIV-1 infection, AIDS

Targets

Target 1
CD3
Gene ID
UniProt ID
Alternative Names
CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3
Target 2
HIV-1 gp41
Gene ID
UniProt ID
Alternative Names
ENV; gp160; Envelope glycoprotein 120; envelope glycoprotein; Envelope surface glycoprotein gp160, precursor; hypothetical protein; Envelope surface glycoprotein gp120; Envelope transmembrane domain; human immunodeficiency virus type 1; human immunodeficiency virus type 1 gp120; human immunodeficiency virus type 1 glycoprotein 120; gp41; GP41; glycoprotein 41
Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.
Online Inquiry

Related products of "CD3 & HIV-1 gp41"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-CD3 x Human Anti-HIV-1 gp41 Bispecific Antibody (Bibody) (BIBD-H261). Click the button below to contact us or submit your feedback about this product.